mRNA |
Vandetanib |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.002 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
-0.15 |
0.003 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.004 |
mRNA |
BRD-K86535717 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
0.004 |
mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.005 |
mRNA |
FGIN-1-27 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
0.005 |
mRNA |
Ki8751 |
CTRPv2 |
pan-cancer |
AAC |
-0.096 |
0.007 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.083 |
0.008 |
mRNA |
CHEMBL1222381 |
CTRPv2 |
pan-cancer |
AAC |
0.088 |
0.008 |
mRNA |
QW-BI-011 |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
0.009 |